3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
4
Neoplasms
3
Virus Diseases
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Kidney Neoplasms
1
Gastrointestinal Cancer Metastatic
1
Carcinoma, Transitional Cell
1
Carcinoma in Situ
1
Breast Neoplasms
1
Adenoviridae Infections
1
Interventions
Gemcitabine
157
Cisplatin
117
pembrolizumab
81
Cystectomy
46
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Docetaxel
39
atezolizumab
33
Magnetic Resonance Spectroscopy
33
Radiotherapy
31
durvalumab
30
avelumab
26
BCG Vaccine
26
Specimen Handling
25
Cystoscopy
24
enfortumab vedotin
23
Doxorubicin
23
Fluorouracil
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Ipilimumab
14
Filgrastim
14
5-aminolevulinic acid hexyl ester
14
Transurethral Resection of Bladder
13
Surgical Procedures, Operative
13
Sunitinib
13
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Interferons
×
Genitourinary
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled